Fig. 2From: Pragmatic pharmacoeconomic analyses by using post-market adverse drug reaction reports: an illustration using infliximab, adalimumab, and the Canada vigilance adverse reaction databaseUncertainty in costs estimated in the probabilistic sensitivity analyses for a. infliximab and b. adalimumab. The shaded areas represent 95 percentile confidence intervalsBack to article page